Back to Journals » Lung Cancer: Targets and Therapy » Volume 5

Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China

Authors Gou L, Wu Y

Received 1 November 2013

Accepted for publication 30 December 2013

Published 12 February 2014 Volume 2014:5 Pages 1—9

DOI https://doi.org/10.2147/LCTT.S40817

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Lan-Ying Gou,1,2 Yi-Long Wu1

1Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, 2Southern Medical University, Guangzhou, People’s Republic of China

Abstract: Lung cancer is a leading cause of cancer-related mortality worldwide and in the People’s Republic of China. Recently, the pathological proportions of the various forms of lung cancer have changed. A shift to a preponderance of adenocarcinoma at the expense of squamous cell carcinoma is observable. Treatment decisions have historically been based on tumor histology, and evolution of our molecular understanding of cancer has led to development of targeted therapeutic agents. It is essential to further understand mutations that drive cancer development (driver mutations) in relevant genes and their effects on cancer cell proliferation and survival. The epidemiology of lung cancer in the People’s Republic of China has been extensively reviewed elsewhere. However, molecular epidemiological data from mainland China are scarce. Consequently, we herein review the prevalence of driver mutations in Chinese patients.

Keywords: lung cancer, driver mutation, prevalence, EGFR, EML4-ALK, KRAS, ROS1, PIK3CA, BRAF, RET, HER2

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]